Skip to main content

United States News All stories

Every story in this section, newest first — page 361 of 373.

Grafa

TrueCar stockholders approve $227M buyout by founder-led Fair Holdings

TrueCar (NASDAQ:TRUE) announced Tuesday that its stockholders have overwhelmingly approved the company’s acquisition by Fair Holdings at a special meeting.

The all-cash transaction, led by TrueCar’s original founder Scott Painter, will take the automotive digital marketplace private in a deal valued at approximately $227 million.

Under the terms of the agreement, TrueCar stockholders will receive $2.55 per share in cash upon closing.

This represents a substantial 72% premium over the company’s closing price on October 14, 2025, the day before the initial announcement.

The deal’s approval follows strong support from major institutional investors and positive recommendations from leading proxy advisory firms ISS and Glass Lewis.

The acquisition marks a full circle for Scott Painter, who founded TrueCar in 2005.

Painter is slated to return as Chief Executive Officer upon the deal’s completion, with a mandate to refocus the platform on profitable growth and deeper integration with its network of over 8,500 certified dealers.

The transaction is expected to close in January 2026, pending the satisfaction of remaining customary closing conditions.

Read more: TrueCar stockholders approve $227M buyout by founder-led Fair Holdings
Grafa
Health

Agenus combination therapy shows durable response in refractory ovarian cancer

Agenus (NASDAQ:AGEN) has published peer-reviewed results from the ovarian cancer cohort of its Phase 1b trial in The Journal for ImmunoTherapy of Cancer (JITC), highlighting a potential breakthrough for a patient population with historically limited options.

Read more: Agenus combination therapy shows durable response in refractory ovarian cancer
Grafa
Health

Novo Nordisk wins FDA nod for Wegovy pill, prepares $149 cash-pay launch

Novo Nordisk A/S (NASDAQ:NVO) received U.S. Food and Drug Administration approval on Monday for the first oral version of its blockbuster weight-loss medication Wegovy, setting the stage for a January launch that will bypass traditional insurance hurdles

Read more: Novo Nordisk wins FDA nod for Wegovy pill, prepares $149 cash-pay launch